SCM
DXCM icon

Silvant Capital Management’s DexCom DXCM Stock Holding History

Silvant Capital Management’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.36M Buy
79,562
+25,387
+47% +$1.69M 0.16% 84
2026
Q1 		$3.4M Buy
54,175
+874
+2% +$60.9K 0.12% 102
2025
Q4 		$3.54M Buy
53,301
+856
+2% +$55.3K 0.12% 101
2025
Q3 		$3.53M Sell
52,445
-4,961
-9% -$393K 0.12% 97
2025
Q2 		$5.01M Buy
57,406
+23,978
+72% +$1.88M 0.19% 74
2025
Q1 		$2.28M Hold
33,428
– – 0.11% 116
2024
Q4 		$2.6M Sell
33,428
-210,159
-86% -$15.6M 0.11% 112
2024
Q3 		$16.3M Sell
243,587
-36,702
-13% -$3.01M 0.72% 24
2024
Q2 		$31.8M Buy
280,289
+18,189
+7% +$2.3M 1.41% 16
2024
Q1 		$36.4M Buy
262,100
+1,082
+0.4% +$136K 1.74% 13
2023
Q4 		$32.4M Buy
261,018
+4,397
+2% +$449K 1.74% 13
2023
Q3 		$23.9M Sell
256,621
-1,243
-0.5% -$140K 1.45% 14
2023
Q2 		$33.1M Buy
257,864
+4,864
+2% +$588K 1.86% 11
2023
Q1 		$29.4M Sell
253,000
-3,082
-1% -$345K 1.91% 11
2022
Q4 		$29M Sell
256,082
-27,954
-10% -$3.07M 2.05% 11
2022
Q3 		$22.9M Buy
284,036
+244,240
+614% +$20.7M 1.56% 13
2022
Q2 		$2.97M Sell
39,796
-128
-0.3% -$11.7K 0.72% 31
2022
Q1 		$5.11M Sell
39,924
-836
-2% -$91.4K 0.97% 19
2021
Q4 		$5.47M Sell
40,760
-6,064
-13% -$871K 0.94% 20
2021
Q3 		$6.4M Sell
46,824
-6,204
-12% -$782K 1.14% 16
2021
Q2 		$5.66M Sell
53,028
-532
-1% -$51.1K 0.89% 24
2021
Q1 		$4.81M Sell
53,560
-928
-2% -$87.1K 0.82% 28
2020
Q4 		$5.04M Sell
54,488
-600
-1% -$53.6K 0.86% 22
2020
Q3 		$5.68M Sell
55,088
-9,440
-15% -$986K 1.06% 19
2020
Q2 		$6.54M Buy
64,528
+5,936
+10% +$531K 1.18% 17
2020
Q1 		$3.94M Sell
58,592
-684
-1% -$42.6K 0.86% 24
2019
Q4 		$3.24M Buy
59,276
+37,740
+175% +$1.79M 0.59% 50
2019
Q3 		$804K Hold
21,536
– – 0.16% 98
2019
Q2 		$807K Hold
21,536
– – 0.14% 99
2019
Q1 		$641K Buy
+21,536
New +$757K 0.12% 102

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Silvant Capital Management's DXCM Position: Q2 2026 in Review

Silvant Capital Management increased its DexCom (DXCM) stake by 47% in Q2 2026, buying an estimated $1.69M and bringing the position to 79,562 shares worth $5.36M. The position accounts for 0.16% of the portfolio, ranked #84.

Silvant Capital Management first reported a position in DXCM in Q1 2019 and has held it in 30 quarters since. The position peaked at $36.4M in Q1 2024. 973 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Silvant Capital Management held 79,562 shares of DexCom worth $5.36M as of Q2 2026.
  • Silvant Capital Management bought 25,387 DexCom shares in Q2 2026, an estimated $1.69M.
  • DexCom made up 0.16% of Silvant Capital Management's portfolio in Q2 2026, its #84 holding.
  • Silvant Capital Management first reported a position in DexCom in Q1 2019 and has held it in 30 quarters since.
  • Silvant Capital Management's DexCom position peaked at $36.4M in Q1 2024.
  • 973 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Silvant Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.